Compare Endeavour Silver Corp (EXK) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Johnson & Johnson — how do they compare? Endeavour Silver Corp trades at $7.47 (market cap $2.36B), while Johnson & Johnson trades at $249.36 (market cap $594.63B). The key difference: Johnson & Johnson is far larger — about 252× Endeavour Silver Corp's market cap, and Johnson & Johnson pays a 2.17% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals.
| EXK | JNJ | |
|---|---|---|
Market Cap | $2.36B | $594.63B |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $267.24 |
52-Week Low | $4.96 | $162.98 |
Enterprise Value | $2.36B | $627.57B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $7.625, down 5.63% today, with a bearish technical signal from moving averages. The company reported a Q1 2026 earnings beat of $0.21 per share versus $0.10 expected, driven by record production. However, 2025 financials show a net loss of $119.1 million despite revenue growth, with negative profit margins and ROE. Analyst consensus is strongly bullish with 11 buy ratings.
Outlook hinges on operational execution and silver price trends. Investment opportunity exists from production growth and potential margin improvement, but risks include sustained negative profitability, high debt-to-asset ratio, and commodity price volatility. Cash flow trends show improvement into 2026, supporting near-term stability.
Johnson & Johnson (JNJ) trades at $249.42, down 1.75% over 24 hours, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q2 2026 EPS of $2.90, beating estimates, and raised full-year guidance. Revenue grew 6.6% annually, supported by strong pharmaceutical sales. Analyst consensus is bullish with a $281 price target, and the stock offers a stable dividend with recent payouts of $1.34 per share.
Outlook remains positive due to robust fundamentals, innovation in medtech and pharmaceuticals, and dividend king status. Risks include patent expirations, regulatory pressures, and macroeconomic volatility. The current valuation at P/E 28.66 may limit near-term upside, but long-term growth prospects appear solid.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
